Skip to main content
Review article

The key role of microRNA-766 in the cancer development

Jitendra GuptaInstitute of Pharmaceutical Research, GLA University, Mathura, IndiaHussein Riyadh Abdul Kareem Al‐HettyDepartment of Nursing, Al-Maarif University College, Ramadi, Anbar, IraqMurtadha Sh. AswoodDepartment of Physics, College of Education, University of Al-Qadisiyah, Al-Diwaniyah, IraqAbduladheem Turki JalilMedical Laboratories Techniques Department, Al-Mustaqbal University College, Babylon, Hilla, IraqMaha Dhurgham AzeezNational University of Science and Technology, Dhi Qar, IraqZafar AminovDepartment of Public Health and Healthcare management, Samarkand State Medical University, Samarkand, UzbekistanFahad AlsaikhanCollege of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi ArabiaAndrés Alexis Ramírez‐CoronelAzogues Campus Nursing Career, Health and Behavior Research Group (HBR), Psychometry and Ethology Laboratory, Catholic University of Cuenca, Cuenca, EcuadorPushpamala RamaiahFaculty of Nursing, Umm al-Qura University, Makkah, Saudi ArabiaBagher FarhoodDepartment of Medical Physics and Radiology, Faculty of Paramedical Sciences, Kashan University of Medical Sciences, Kashan, Iran
Frontiers in Oncologyjournal2023en
ABI

Abstract

Cancer is caused by defects in coding and non-coding RNAs. In addition, duplicated biological pathways diminish the efficacy of mono target cancer drugs. MicroRNAs (miRNAs) are short, endogenous, non-coding RNAs that regulate many target genes and play a crucial role in physiological processes such as cell division, differentiation, cell cycle, proliferation, and apoptosis, which are frequently disrupted in diseases such as cancer. MiR-766, one of the most adaptable and highly conserved microRNAs, is notably overexpressed in several diseases, including malignant tumors. Variations in miR-766 expression are linked to various pathological and physiological processes. Additionally, miR-766 promotes therapeutic resistance pathways in various types of tumors. Here, we present and discuss evidence implicating miR-766 in the development of cancer and treatment resistance. In addition, we discuss the potential applications of miR-766 as a therapeutic cancer target, diagnostic biomarker, and prognostic indicator. This may shed light on the development of novel therapeutic strategies for cancer therapy.

Topics

Identifiers

Citations and references